Overall Revision Summary - The company has revised its Articles of Association to enhance governance structure and compliance with the updated Company Law and relevant regulations [1][2] - The company will abolish the supervisory board and its rules, transferring its responsibilities to the Audit and Risk Control Committee of the board [2][3] Key Amendments to Articles of Association - The term "Shareholders' Meeting" has been standardized to "Shareholders' Assembly," and new sections regarding controlling shareholders, independent directors, and board committees have been added [2][3] - The company will no longer have a supervisory board, and the current supervisors will cease their roles, with the Audit and Risk Control Committee assuming the supervisory functions [2][3] - The revised Articles emphasize the importance of legal compliance and governance, aligning with the principles of the Communist Party of China [4][5] Governance and Management Structure - The Articles outline the responsibilities of the board of directors as the legal representatives of the company, including the appointment of a new legal representative within 30 days if the current one resigns [3][4] - The company aims to strengthen its legal governance and compliance management, ensuring the protection of the rights of shareholders and creditors [4][5] Company Mission and Values - The company’s mission is to enhance the quality of life through technological advancement and integrity, focusing on high-quality development and maximizing shareholder value [6][7] - The company is committed to becoming a trusted global provider of pharmaceutical and medical device services, contributing to national health initiatives and the Belt and Road Initiative [6][7] Shareholder Rights and Responsibilities - Shareholders have the right to receive dividends and participate in decision-making processes, including the right to request meetings and propose agenda items [12][13] - The company emphasizes the obligation of shareholders to comply with laws and regulations, ensuring responsible exercise of their rights [18][19] Financial and Operational Governance - The company will implement strict regulations regarding external guarantees, requiring shareholder approval for guarantees exceeding certain thresholds [25][26] - The Articles stipulate that the company must maintain transparency in its financial dealings and adhere to regulatory requirements for information disclosure [26][27]

Group 1 - The core viewpoint is that the Chinese biotech industry is experiencing significant growth, supported by substantial investments and a positive outlook for domestic innovative drug development [1][2] - The CSI Medical and Medical Device Innovation Index (931484) has shown a 0.45% increase, with notable gains from stocks such as Aier Eye Hospital (688578) up 5.62% and Innovent Biologics (688278) up 2.57% [1] - The Medical Innovation ETF (516820) has also seen a 0.29% increase, reflecting a positive trend in the sector [1] Group 2 - The CSI Medical and Medical Device Innovation Index includes 30 companies with strong profitability and growth potential, representing a significant portion of the industry [2] - As of April 30, 2025, the top ten weighted stocks in the index account for 66.51% of the total index, highlighting the concentration of performance among leading companies [2] - The upcoming ASCO conference is expected to provide further data that could positively impact related companies, indicating ongoing advancements in cancer treatment [1]